Top

Published in:

01-05-2017 | Original Article

HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy

Authors: Masatoshi Takagi, Yasuyoshi Ishiwata, Yuki Aoki, Satoshi Miyamoto, Akihiro Hoshino, Kazuaki Matsumoto, Akira Nishimura, Mari Tanaka, Masakatsu Yanagimachi, Noriko Mitsuiki, Kohsuke Imai, Hirokazu Kanegane, Michiko Kajiwara, Kanako Takikawa, Tsukasa Mae, Osamu Tomita, Junya Fujimura, Masato Yasuhara, Daisuke Tomizawa, Shuki Mizutani, Tomohiro Morio

Published in: International Journal of Hematology | Issue 5/2017

Abstract

Haploidentical hematopoietic cell transplantation (HCT) conditioning with clofarabine and target area under the blood concentration–time curve (AUC)-based busulfan adjustment was performed in three patients with refractory pediatric leukemia. The target AUC for two patients who had already received multiple transplantations was 3600 and 4000 μmol min/L, and that for the patient with Down’s syndrome was 3000 μmol min/L. Regimen-related toxicity was well tolerated in all cases. All three maintained cytological remission throughout the follow-up period (between 31 and 167 weeks). Thus, haploidentical HCT conditioning with clofarabine and target AUC-based busulfan adjustment may be a preferable option for children with recurrent or refractory pediatric leukemia.

Inagaki J, Fukano R, Noguchi M, Kurauchi K, Tanioka S, Okamura J. Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children. Pediatr Blood Cancer. 2015;62:674–9. doi:10.1002/pbc.25353.CrossRefPubMed

Poon LM, Bassett R Jr, Rondon G, Hamdi A, Qazilbash M, Hosing C, et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013;48:666–70. doi:10.1038/bmt.2012.195.CrossRefPubMed

Chevallier P, Labopin M, Buchholz S, Ganser A, Ciceri F, Lioure B, et al. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol. 2012;89:214–9. doi:10.1111/j.1600-0609.2012.01822.x.CrossRefPubMed

Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, et al. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1819–26. doi:10.1016/j.bbmt.2012.06.010.CrossRefPubMedPubMedCentral

Magenau J, Tobai H, Pawarode A, Braun T, Peres E, Reddy P, et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011;118:4258–64. doi:10.1182/blood-2011-06-358010.CrossRefPubMed

Watanabe E, Nishikawa T, Ikawa K, Yamaguchi H, Abematsu T, Nakagawa S, et al. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients. Int J Hematol. 2015;102:611–6. doi:10.1007/s12185-015-1853-6.CrossRefPubMed

Aoki Y, Miyawaki R, Imai K, Takagi M, Kajiwara M, Ishiwata Y, et al. Haploidentical bone marrow transplantation with clofarabine and busulfan conditioning for a child with multiple recurrent acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2016;38:e39–41. doi:10.1097/MPH.0000000000000454.CrossRefPubMed

Bleyzac N, Barou P, Aulagner G. Rapid and sensitive high-performance liquid chromatographic method for busulfan assay in plasma. J Chromatogr B Biomed Sci Appl. 2000;742:427–32.CrossRefPubMed

Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009;27:4392–7. doi:10.1200/JCO.2008.18.8706.CrossRefPubMedPubMedCentral

10.

Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118:6043–9. doi:10.1182/blood-2011-08-374710.CrossRefPubMedPubMedCentral

11.

Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468–76.CrossRefPubMed

12.

Ryu SG, Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13:1095–105. doi:10.1016/j.bbmt.2007.06.005.CrossRefPubMed

13.

Ward J, Kletzel M, Duerst R, Fuleihan R, Chaudhury S, Schneiderman J, et al. Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation. Biol Blood Marrow Transplant. 2015;21:1612–21. doi:10.1016/j.bbmt.2015.05.017.CrossRefPubMed

14.

Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:88–98. doi:10.1016/j.bbmt.2007.09.015.CrossRefPubMed

15.

Gonzalez-Vicent M, Molina B, Perez A, Diaz MA. Once-daily intravenous busulfan for 47 pediatric patients undergoing autologous hematopoietic stem cell transplantation: a single center study. J Pediatr Hematol Oncol. 2012;34:180–3. doi:10.1097/MPH.0b013e3182431e1b.CrossRefPubMed

16.

Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, et al. Intravenous busulfan-based myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2016;22:1424–30. doi:10.1016/j.bbmt.2016.04.013.CrossRefPubMed

17.

Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, et al. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;. doi:10.1038/bmt.2016.188.PubMedCentral

Title: HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy
Authors: Masatoshi Takagi
Yasuyoshi Ishiwata
Yuki Aoki
Satoshi Miyamoto
Akihiro Hoshino
Kazuaki Matsumoto
Akira Nishimura
Mari Tanaka
Masakatsu Yanagimachi
Noriko Mitsuiki
Kohsuke Imai
Hirokazu Kanegane
Michiko Kajiwara
Kanako Takikawa
Tsukasa Mae
Osamu Tomita
Junya Fujimura
Masato Yasuhara
Daisuke Tomizawa
Shuki Mizutani
Tomohiro Morio
Publication date: 01-05-2017
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 5/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-017-2187-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

5q− syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10)

Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment

Body mass index is a prognostic factor in adult patients with acute myeloid leukemia

Bortezomib interferes with adhesion of B cell precursor acute lymphoblastic leukemia cells through SPARC up-regulation in human bone marrow mesenchymal stromal/stem cells

CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma

Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum

Keynote webinar | Spotlight on antibody–drug conjugates in cancer